Menu Search
Equities

Lexaria Bioscience Corp

LEXX:NAQ

Lexaria Bioscience Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.36
  • Today's Change0.04 / 1.72%
  • Shares traded210.34k
  • 1 Year change+50.80%
  • Beta1.0974
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lexaria Bioscience Corp had revenues fall -11.43% from 255.40k to 226.21k, though the company grew net income from a loss of 7.27m to a smaller loss of 6.66m.
Gross margin98.83%
Net profit margin-1,185.15%
Operating margin-1,185.16%
Return on assets-63.85%
Return on equity-66.81%
Return on investment-65.93%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Lexaria Bioscience Corp fell by 4.46m. Cash Flow from Financing totalled 1.59m or 702.77% of revenues. In addition the company used 5.88m for operations while cash used for investing totalled 169.61k.
Cash flow per share-0.4757
Price/Cash flow per share--
Book value per share0.6403
Tangible book value per share0.6087
More ▼

Balance sheet in USDView more

Lexaria Bioscience Corp has little financial risk as the capital structure does not rely on leverage.
Current ratio58.27
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.